Literature DB >> 14593002

Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries.

Arundhathi Jeyabalan1, Jacqueline Novak, Lee A Danielson, Laurie J Kerchner, Shannon L Opett, Kirk P Conrad.   

Abstract

During pregnancy, relaxin stimulates nitric oxide (NO)-dependent renal vasodilation, hyperfiltration and reduced myogenic reactivity of small renal arteries via the endothelial ETB receptor subtype. Our objective in this study was to elucidate the mechanisms by which relaxin stimulates the endothelial ETB receptor/NO vasodilatory pathway. Using chronically instrumented conscious rats, we demonstrated that a specific peptide inhibitor of the gelatinases MMP-2 and -9, cyclic CTTHWGFTLC (cyclic CTT), but not the control peptide, STTHWGFTLS (STT), completely reversed renal vasodilation and hyperfiltration in relaxin-treated rats. Comparable findings were observed with a structurally different and well-established, general antagonist of MMPs, GM6001. In contrast, phosphoramidon, an inhibitor of endothelin-converting enzyme, did not significantly change the renal vasodilatory response to relaxin administration. When small renal arteries were incubated with either of the general MMP inhibitors, GM6001 or TIMP-2 (tissue inhibitor of MMP), or with the specific gelatinase inhibitor, cyclic CTT, the reduced myogenic reactivity of these blood vessels from relaxin-treated nonpregnant and midterm pregnant rats was totally abolished. Moreover, a neutralizing antibody specific for MMP-2 completely abrogated the reduced myogenic reactivity of small renal arteries from relaxin-treated nonpregnant and midterm pregnant rats. In contrast, phosphoramidon did not significantly affect the reduction in myogenic reactivity. Using gelatin zymography, we showed increased pro and active MMP-2 activity in small renal arteries from relaxin-treated nonpregnant and midterm pregnant rats relative to the control animals. Thus, inhibitors of MMPs in general and of gelatinases in particular reverse the renal vascular changes induced by pregnancy or relaxin administration to nonpregnant rats. Finally, the typical reduction in myogenic reactivity of small renal arteries from relaxin-treated nonpregnant rats was absent in ETB receptor-deficient rats, despite an increase in vascular MMP-2 activity. These results indicate an essential role for vascular gelatinase, which is in series with, and upstream of, the endothelial ETB receptor/NO signaling pathway in the renal vasodilatory response to relaxin and pregnancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593002     DOI: 10.1161/01.RES.0000104086.43830.6C

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  48 in total

Review 1.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 2.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 3.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 4.  Plasticity of the Maternal Vasculature During Pregnancy.

Authors:  George Osol; Nga Ling Ko; Maurizio Mandalà
Journal:  Annu Rev Physiol       Date:  2019-02-10       Impact factor: 19.318

5.  Metalloproteinases in hypertension and cardiac disease: differential expression and mutual regulation.

Authors:  Ana-Maria Bosonea; Xiang Wang; Jeffrey Odenbach; Carlos Fernandez-Patron
Journal:  Drug Discov Today Dis Models       Date:  2011

Review 6.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 8.  Are we getting closer to a Nobel prize for unraveling preeclampsia?

Authors:  Ralf Dechend; Friedrich C Luft
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

9.  Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

Review 10.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.